MINIMAL RESIDUAL DISEASE MONITORING AND DEPTH OF RESPONSE IN MULTIPLE MYELOMA

EHA Library, Joaquin martinez-lopez, 266429

HEALTH-RELATED QUALITY OF LIFE WITH POMALIDOMIDE + LOW-DOSE DEXAMETHASONE + DARATUMUMAB IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA AFTER LENALIDOMIDE TREATMENT

EHA Library, Donna Reece, 266430

EARLY SALVAGE TREATMENT WITH SECOND-GENERATION NOVEL AGENTS AT BIOCHEMICAL RELAPSE PROLONGS OVERALL SURVIVAL: A REAL-WORLD SINGLE CENTER EXPERIENCE

EHA Library, Francesco Di Raimondo, 266431

PROGNOSTIC VALUE OF KIDNEY BIOPSY INTERSTITIAL FIBROSIS IN REVERSIBILITY OF DIALYSIS-DEPENDENT ACUTE KIDNEY INJURY DUE TO MYELOMA CAST NEPHROPATHY

EHA Library, Evgeniia KAZARINA, 266432

OUTCOMES OF SALVAGE WITH INFUSIONAL REGIMENS DT-PACE/ESHAP FOR REFRACTORY OR RELAPSED MULTIPLE MYELOMA (MM)

EHA Library, Louise Ainley, 266433

SERUM ERYTHROPOIETIN IS A PREDICTIVE FACTOR OF RENAL REVERSIBILITY IN RENAL IMPAIRMENT IN MULTIPLE MYELOMA PATIENTS

EHA Library, Hiroki Kobayashi, 266434

NATURAL KILLER CELL ALLOREACTIVE HAPLOIDENTICAL STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA PATIENTS

EHA Library, Catharina Van Elssen, 266435

EFFICACY OF LENALIDOMIDE AND LOW-DOSE DEXAMETHASONE IN NEWLY DIAGNOSED PATIENTS WITH MULTIPLE MYELOMA: RESULTS FROM A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIAL EVIDENCE

EHA Library, Thierry Facon, 266436

Real world data examining the use of Ixazomib, Lenalidomide and Dexamethasone (ILD) and Lenalidomide and Dexamethasone (LD) chemotherapy in Multiple Myeloma

EHA Library, Keonwoo Yi, 266437

IMMUNE ELECTRON MICROSCOPY AND MASS SPECTROMETRY FOR CLASSIFICATION OF AMYLOID DEPOSITS

EHA Library, Niels Abildgaard, 266438

MULTIPLE MYELOMA TREATMENT LANDSCAPE FROM 2011 TO 2017 IN ALBERTA, CANADA: RESULTS FROM THE POPULATION-BASED “IDENTIFYING OUTCOMES IN REAL-WORLD MULTIPLE MYELOMA” (INFORMM) STUDY

EHA Library, Victor H. Jimenez-Zepeda, 266439

CHARACTERIZATION OF TREATMENTS AND REAL-LIFE OUTCOMES IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WHO RECEIVED FRONTLINE AUTOLOGOUS STEM CELL TRANSPLANTATION IN SWEDEN

EHA Library, F Borgsten, 266440

REDUCED INTENSITY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IS A SAFE AND EFFECTIVE TREATMENT OPTION IN HIGH RISK MYELOMA PATIENTS - A SINGLE CENTRE EXPERIENCE

EHA Library, Amanda Jurgensen-Rauch, 266441

CHARACTERIZATION OF FRONTLINE TREATMENT PATTERNS AND THE PROPORTION OF PATIENTS REACHING SUBSEQUENT LINES OF THERAPY IN TRANSPLANT ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Peter M. Voorhees, 266442

CARFILZOMIB, LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: THE REAL LIFE EXPERIENCE OF RETE EMATOLOGICA PUGLIESE (REP).

EHA Library, Anna Mele, 266443

EXPOSURE-RESPONSE ANALYSIS & DISEASE MODELING FOR SELECTION OF OPTIMAL DOSING REGIMEN OF ISATUXIMAB AS SINGLE AGENT IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Hoai Thu Thai, 266444

ASSOCIATION BETWEEN BORTEZOMIB CUMULATIVE DOSE AND TREATMENT-FREE INTERVAL IN TRANSPLANT-INELIGIBLE PATIENTS WITH PREVIOUSLY UNTREATED MULTIPLE MYELOMA

EHA Library, Jianming He, 266445

THE PROGNOSTIC IMPACT OF PATHOLOGIC FRACTURE AS MYELOMA-DEFINING EVENT IN NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Rafael Rios-Tamayo, 266446

TREATMENT PATTERNS FOR MULTIPLE MYELOMA PATIENTS: A RETROSPECTIVE COHORT STUDY IN U.S. ELECTRONIC MEDICAL RECORDS DATABASE 2012-2018

EHA Library, PARAMESWARAN HARI, 266447

ALPINA: REAL WORLD ANALYSIS OF 1ST LINE RVD TREATMENT IN TRANSPLANT ELIGIBLE AND TRANSPLANT-NON-ELIGIBLE MM PATIENTS WITH A FOCUS ON TOLERABILITY AND EFFICACY

EHA Library, Wolfgang Willenbacher, 266448

AGE DOES NOT CONFER DIFFERENT FEATURES AND OUTCOMES IN PATIENTS WITH NEWLY DIAGNOSED ACTIVE MULTIPLE MYELOMA YOUNGER THAN 66 YEARS OF AGE TREATED IN A RECENT PERIOD.

EHA Library, Eloísa Riva, 266449

POMALIDOMIDE, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS IN A REAL LIFE SETTING: A SINGLE CENTER RETROSPECTIVE STUDY

EHA Library, Sabrina Trudel, 266450

EPIGENETIC ALTERATION OF CSK BINDING PROTEIN(CBP) IN MYELOPROLIFERATIVE NEOPLASMS COMPLEMENTS THE JAK2V617F MUTATION

EHA Library, Jian HUANG, 266453

PROGNOSTIC RELEVANCE OF THE GENE EXPRESSION SIGNATURE IN PRIMARY AND SECONDARY MYELOFIBROSIS

EHA Library, Sebastiano Rontauroli, 266454

EXPRESSION OF CD47 AND CALR IN MYELOPROLIFERATIVE NEOPLASMS: POTENTIAL NEW THERAPEUTICAL TARGETS

EHA Library, Kristian BOASMAN, 266455

USE OF A NGS MYELOID PANEL TO FIND CLONALITY IN TRIPLE NEGATIVE ESSENTIAL THROMBOCYTHEMIA. IDENTIFICATION OF NEW MUTATIONS IN DRIVER GENES

EHA Library, Gonzalo Carreno Gomez-Tarragona, 266456

THE NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) IS A CHEAP SURROGATE OF EXPANSION OF MYELOID-DERIVED SUPPRESSOR CELLS IN MYELOFIBROSIS BEFORE AND AFTER TREATMENT WITH RUXOLITINIB: A SINGLE-CENTER EXPERIENCE

EHA Library, ALESSANDRA ROMANO, 266457

MYELOMONOCYTIC SKEWING IN VITRO DISCRIMINATES SUBGROUPS OF PATIENTS WITH MYELOFIBROSIS WITH A DIFFERENT PHENOTYPE, A DIFFERENT GENOTYPE AND DIFFERENT PROGNOSIS

EHA Library, Klaus Geissler, 266458

TRANSCRIPTIONAL PROFILES OF PRIMARY CULTURES OF ERYTHROID AND MEGAKARYOCYTIC CELLS IN ESSENTIAL THROMBOCYTHEMIA UNCOVER A HIGH DEGREE OF GENE DEREGULATION IN THE MEGAKARYOCYTIC LINEAGE.

EHA Library, Petros Papadopoulos, 266459

MOLECULAR PROFILING REVEALS HIGHLY DEREGULATED INSULIN GROWTH FACTOR BINDING PROTEINS IN PATIENTS WITH MYELOFIBROSIS AND RELATED NEOPLASMS

EHA Library, Vibe Skov, 266460

MICRORNA EXPRESSION PROFILE IN CHRONIC MYELOPROLIFERATIVE NEOPLASMS: THE IMPACT OF 3 MONTHS IMMUNE THERAPY USING PEGYLATED INTERFERON-ALPHA2.

EHA Library, Morten K Larsen, 266461

TRANSCRIPTION ALTERATION OF DNA REPAIR GENES IN PHILADELPHIA CHROMOSOME NEGATIVE MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Martin KIRSCHNER, 266462

46/1 HAPLOTYPE IS ASSOCIATED WITH A HIGHER MONOCYTE/LYMPHOCYTE RATIO IN HEALTHY INDIVIDUALS

EHA Library, Gonzalo Carreno Gomez-Tarragona, 266463

SERUM FERRITIN LEVELS ARE INCREASED IN IDIOPATHIC ERYTHROCYTOSIS BUT REDUCED IN POLYCYTHEMIA VERA

EHA Library, Giacomo Biagetti, 266464

LOW JAK2 V617F ALLELE BURDEN PHI-NEGATIVE CHRONIC MYELOPROLIFERATIVE NEOPLASMS MAY ASSOCIATE WITH ADDITIONAL CALR OR MPL MUTATIONS.

EHA Library, Tatiana Makarik, 266465

THE ROLE OF HEPCIDIN AND DYSREGULATED IRON HOMEOSTASIS IN THE PATHOGENESIS OF ANEMIA IN MYELOFIBROSIS

EHA Library, Stela Dimitrova, 266466

RESULTS FROM ONGOING PHASE 1/2 CLINICAL TRIAL OF TAGRAXOFUSP (SL-401) IN PATIENTS WITH INTERMEDIATE, OR HIGH RISK, RELAPSED/REFRACTORY MYELOFIBROSIS

EHA Library, Naveen Pemmaraju, 266467

RUXOLITINIB TREATMENT AND RISK OF B-CELL LYMPHOMAS IN MYELOPROLIFERATIVE NEOPLASMS

EHA Library, Chiara Cavalloni, 266468

MOLECULAR CLASSIFICATION OF PATIENTS WITH POLYCYTHEMIA VERA OR ESSENTIAL THROMBOCYTHEMIA WHO DEVELOP RESISTANCE OR INTOLERANCE TO HYDROXYUREA

EHA Library, Álvaro Díaz González, 266469

RATE OF THROMBOSIS IN CONTEMPORARY PATIENTS WITH POLYCYTHEMIA VERA UNDER HYDROXYUREA REMAINS EXCEEDINGLY HIGH. RESULTS OF SYSTEMATIC REVIEW AND METANALYSIS.

EHA Library, Alberto Ferrari, 266470

RESULTS FROM ONGOING PHASE 1/2 CLINICAL TRIAL OF TAGRAXOFUSP (SL-401) IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)

EHA Library, Hassan Alkhateeb, 266471

PHASE 1/2 STUDY OF RUXOLITINIB (RUX) PLUS DECITABINE (DAC) IN PATIENTS (PTS) WITH POST-MYELOPROLIFERATIVE NEOPLASM ACUTE MYELOID LEUKEMIA (POST-MPN AML)

EHA Library, Prithviraj Bose, 266472

OUTCOME OF PATIENTS WITH MYELOFIBROSIS AFTER RUXOLITINIB DISCONTINUATION: ROLE OF DISEASE STATUS AND TREATMENT STRATEGIES IN 218 PATIENTS

EHA Library, Giuseppe Palumbo, 266473

JAK2V617F AND MPL MUTATIONS ARE ASSOCIATED WITH WORSENED SYMPTOM BURDEN THAN CALR IN THE MYELOPROLIFERATIVE NEOPLASMS: FINDINGS FROM THE MYMPN PATIENT REGISTRY

EHA Library, Robyn Scherber, 266474

BODY MASS INDEX AND TOTAL SYMPTOM BURDEN IN MYELOPROLIFERATIVE NEOPLASMS - DISCOVERY OF A U-SHAPED ASSOCIATION

EHA Library, Robyn Scherber, 266475

DNA HYPERMETHYLATION EMERGES AS THE STRONGEST PREDICTOR FOR POOR OUTCOME AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN JUVENILE MYELOMONOCYTIC LEUKEMIA (JMML)

EHA Library, Charlotte Niemeyer, 266476

MOLECULAR PROFILE AND RISK OF THROMBOSIS IN JAK2V617F POLYCYTHEMIA VERA PATIENTS

EHA Library, Anna Angona Figeuras, 266477

REAL-WORLD SAFETY DATA FROM A NONINTERVENTIONAL LONG-TERM POSTAUTHORIZATION SAFETY STUDY OF RUXOLITINIB IN MYELOFIBROSIS

EHA Library, Fiorenza BARRACO, 266478

MAJOR OR CLINICALLY RELEVANT NON-MAJOR HEMORRHAGIC EVENTS IN A LARGE POPULATION OF PATIENTS WITH POLYCYTHEMIA VERA OR ESSENTIAL THROMBOCYTHEMIA: LOCALIZATION, CONSEQUENCES AND DRUG USE

EHA Library, Christophe Nicol, 266479

IMPACT OF MYELOPROLIFERATIVE NEOPLASMS (MPNS) AND PERCEPTIONS OF TREATMENT GOALS AMONGST PHYSICIANS AND PATIENTS IN 6 COUNTRIES: AN EXPANSION OF THE MPN LANDMARK SURVEY

EHA Library, Guray Saydam, 266480

MULTICENTER RETROSPECTIVE STUDY EVALUATING FIBROSIS RISK IN PATIENTS WITH ET DEPENDING ON THE TREATMENT SCENARIO

EHA Library, Marta Sobas, 266481

ARTERIAL THROMBOSIS IN YOUNG PV PATIENTS

EHA Library, Giulia Bogoni, 266482

ANAGRELIDE MODULATES PROPLATELET FORMATION RESULTING IN DECREASED NUMBER AND INCREASED SIZE OF PLATELETS

EHA Library, Naohiro Miyashita, 266483

THE RELATIONSHIP BETWEEN TOTAL ANTIOXIDANT CAPACITY AND JAK2V617F MUTATION IN ESSENTIAL THROMBOCYTHEMIA

EHA Library, Mihnea-Alexandru Găman, 266484

HEALTHCARE RESOURCE IMPLICATIONS IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASMS AND SPLANCHNIC VEIN THROMBOSIS

EHA Library, Ximena Cabrera Castellano, 266485

RISK OF THROMBOSIS IN PATIENTS WITH POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA ACCORDING TO THE JAK2 V617F ALLELE BURDEN

EHA Library, Sung Hwa Bae, 266486

JAK2 ALLELIC RATIO IMPACTS ON VASCULAR EVENT IN MYELOFIBROSIS BY INCREASING THE RISK OF THROMBOSIS. A SINGLE CENTER EXPERIENCE ON 150 PATIENTS.

EHA Library, Mirko Farina, 266487

SAFETY AND EFFICACY OF ROMIPLOSTIM IN OVER 200 CHILDREN WITH PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) IN AN INTEGRATED DATABASE OF 5 CLINICAL TRIALS

EHA Library, Nichola Cooper, 266488

PREDICTORS OF THERAPY FREE RESPONSES IN ITP PATIENTS RECEIVING TPO-RA. RESULTS FROM A SPANISH MULTICENTER STUDY

EHA Library, Maria L Lozano, 266489

SPLENECTOMY IN IMMUNE THROMBOCYTOPENIA: DO CHANGING TREATMENT PATTERNS FOR ITP AFFECT OUTCOMES? DATA FROM THE UK ITP REGISTRY

EHA Library, Sophie Todd, 266490

COMBINATION OF MYCOPHENOLATE MOFETIL AND DEXAMETHASONE IN THE PATIENTS OF CHRONIC ITP

EHA Library, nilesh wasekar, 266491

PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN THE ELRDELRY AND YOUNGER ADULTS: REAL-WORLD COMPARATIVE RETROSPECTIVE STUDY FROM THE ITP REGISTRY OF THE HELLENIC SOCIETY OF HEMATOLOGY

EHA Library, Charalampos Pontikoglou, 266492

TREATMENT-FREE REMISSION AFTER TPO RECEPTOR AGONISTS IN ADULT ITP PATIENTS IN BELGIUM

EHA Library, Ann Janssens, 266493

ELTROMBOPAG AS SECOND LINE THERAPY IN ADULT PATIENTS WITH PRIMARY IMMUNE THROMBOCYTOPENIA (ITP) IN ATTEMPT TO TREATMENT-FREE REMISSION. UPDATED RESULTS OF A PHASE II PROSPECTIVE STUDY BY GIMEMA GROUP

EHA Library, Elisa Lucchini, 266494

SAFETY AND EFFICACY OF SELF-ADMINISTERED ROMIPLOSTIM IN PATIENTS WITH IMMUNE THROMBOCYTOPENIA (ITP): RESULTS OF AN INTEGRATED ANALYSIS OF FIVE CLINICAL TRIALS

EHA Library, Dominik Selleslag, 266495

LUSUTROMBOPAG IS A SAFE AND EFFICACIOUS TREATMENT OPTION FOR THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC LIVER DISEASE UNDERGOING PLANNED INVASIVE PROCEDURES: INTEGRATED ANALYSIS OF TWO PHASE 3 TRIALS

EHA Library, Robert Brown, 266496

LUSUTROMBOPAG RELIABLY INCREASES PLATELETS REGARDLESS OF BASELINE PLATELET COUNTS IN THROMBOCYTOPENIC CHRONIC LIVER DISEASE PATIENTS UNDERGOING PLANNED INVASIVE PROCEDURES: RESULTS OF 2 PHASE 3 TRIALS

EHA Library, Robert Brown, 266497

LUSUTROMBOPAG IS A SAFE TREATMENT OPTION FOR THROMBOCYTOPENIA IN PATIENTS WITH CHRONIC LIVER DISEASE UNDERGOING A SCHEDULED INVASIVE PROCEDURE: POOLED SAFETY ANALYSIS FROM 3 STUDIES

EHA Library, Robert Brown, 266498

REAL-WORLD DATA DEMONSTRATE SAFETY AND EFFECTIVENESS OF LUSUTROMBOPAG IN CHRONIC LIVER DISEASE PATIENTS WITH THROMBOCYTOPENIA UNDERGOING PLANNED INVASIVE PROCEDURES: INTERIM ANALYSIS

EHA Library, Fabio De Gregorio, 266499

ASSESSMENT OF ELTROMBOPAG IN PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA UNDER ROUTINE CLINICAL PRACTICE IN THE MIDDLE EAST, TURKEY, ASIA, AND AUSTRALIA

EHA Library, Raymond S.M. Wong, 266500

USE OF THE THROMBOPOIETIN RECEPTOR AGONIST LUSUTROMBOPAG FOR THROMBOCYTOPENIA IN PATIENTS WITH HEPATOCELLULAR CARCINOMA UNDERGOING PLANNED INVASIVE PROCEDURES: INTEGRATED ANALYSIS OF 2 TRIALS

EHA Library, Naim Alkhouri, 266501

LONG-TERM FOSTAMATINIB TREATMENT OF ADULTS WITH IMMUNE THROMBOCYTOPENIA (ITP) DURING THE PHASE 3 CLINICAL TRIAL PROGRAM

EHA Library, James Bussel, 266502

CHARACTERISTICS OF PATIENTS WITH CYCLIC THROMBOCYTOPENIA: AN OBSERVATIONAL STUDY

EHA Library, Oskar Steinbrecher, 266503

PATIENTS WITH CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) SHOW IMPAIRED COGNITIVE FUNCTION

EHA Library, Camelia Vladescu, 266504

OCCULT BLEEDING IN CHILDREN WITH IMMUNE THROMBOCYTOPENIA: RELATION TO LABORATORY PARAMETERS &ITP HEALTH QUALITY OF LIFE.

EHA Library, AZZA ABDELGAWAD TANTAWY ZAGHLOUL, 266505

INCIDENCE AND OUTCOMES OF REFRACTORY IMMUNE THROMBOCYTOPENIC PURPURA IN CHILDREN; A SINGLE INSTITUTION EXPERIENCE

EHA Library, Masataka Ito, 266506

THE IMPACT OF ANTIPHOSPHOLIPID ANTIBODIES (APL) ON OUTCOMES OF PATIENTS WITH IMMUNE THROMBOCYTOPENIA AND AUTOIMMUNE HEMOLYTIC ANEMIA TREATED WITH SPLENECTOMY.

EHA Library, Juan Rangel-Patino, 266507

TAPERING AND DISCONTINUATION OF THROMBOPOIETIN RECEPTOR AGONISTS IN ITP: EXPERT CONSENSUS OPINIONS

EHA Library, Nichola Cooper, 266508

LONG-TERM OVERUSE OF CORTICOSTEROIDS IN THE REAL-WORLD TREATMENT OF PATIENTS WITH IMMUNE THROMBOCYTOPENIA IN THE US EXPLORYS AND MARKETSCAN DATABASES

EHA Library, James Bussel, 266509

DIFFERENCES IN PERCEPTIONS ON TREATMENT APPROACHES BETWEEN PHYSICIANS AND ITP PATIENTS: RESULTS FROM THE ITP WORLD IMPACT SURVEY (I-WISH)

EHA Library, Alexandra Kruse, 266510

PHYSICIANS’ PERCEPTIONS ON CAUSES OF PRIMARY AND SECONDARY ITP AND LEADING CAUSES OF MISDIAGNOSIS: RESULTS FROM THE ITP WORLD IMPACT SURVEY (I-WISH)

EHA Library, James Bussel, 266511

THERE ARE NO PREDICTIVE FACTORS ASSOCIATED WITH GOOD THERAPY RESPONSE TO SPLENECTOMY FOR PRIMARY IMMUNE THROMBOCYTOPENIA - CONCLUSION BASED ON SYSTEMATIC REVIEW AND META-ANALYSIS

EHA Library, Mirjana Mitrovic, 266512

PATIENT PERCEPTIONS ON SPLENECTOMY OUTCOMES: RESULTS FROM THE ITP WORLD IMPACT SURVEY (I-WISH)

EHA Library, Nichola Cooper, 266513

THE IMPACT OF CRIZANLIZUMAB ON VOC-RELATED MEDICAL FACILITY VISITS

EHA Library, Miranda Bailey, 266514

CLINICAL IMPACT OF PROGNOSTIC NUTRITIONAL INDEX IN DIFFUSE LARGE B CELL LYMPHOMA

EHA Library, Gyeong-Won Lee, 266515

QUALITY OF LIFE (QOL), PERSPECTIVES ON TREATMENT AND IMPORTANT OUTCOMES FOR MULTIPLE MYELOMA (MM) PATIENTS AND THEIR CARERS: A MIXED METHODS EVIDENCE SYNTHESIS

EHA Library, Jayne Galinsky, 266516

THE ECONOMIC AND HUMANISTIC BURDEN OF GRAFT-VERSUS-HOST DISEASE (GVHD) IN PEDIATRIC PATIENTS: A SYSTEMATIC LITERATURE REVIEW (SLR)

EHA Library, Anna Forsythe, 266517

CLINICAL OUTCOMES OF SOLID ORGAN TRANSPLANT PATIENTS WITH EBV+PTLD WHO FAIL FIRST-LINE RITUXIMAB OR RITUXIMAB PLUS CHEMOTHERAPY: AN ANALYSIS OF GERMAN PTLD REGISTRY

EHA Library, Heiner Zimmermann, 266518

MEDICAL COSTS ASSOCIATED WITH RELAPSE AMONG PATIENTS WITH FOLLICULAR LYMPHOMA

EHA Library, Sheila R. Reddy, 266519

MINIMAL CLINICALLY IMPORTANT DIFFERENCE AND RESPONSIVENESS FOR HM-PRO IN PATIENTS WITH HAEMATOLOGICAL MALIGNANCIES

EHA Library, Pushpendra Goswami, 266520

SYMPTOMS AND HEALTH-RELATED QUALITY OF LIFE OF PATIENTS ONE YEAR AFTER ALLOGENEIC HAEMATOPOIETIC STEM CELL TRANSPLANTATION

EHA Library, Simone Oerlemans, 266521

TEN YEARS OF CLINICAL EXPERIENCE WITH BIOSIMILAR FILGRASTIM IN ONCOLOGY AND HAEMATOLOGY

EHA Library, Pere Gascón, 266522

PATIENT CHARACTERISTICS, TREATMENTS AND TRANSPLANT FREQUENCY IN NEWLY-DIAGNOSED (NDMM) MULTIPLE MYELOMA

EHA Library, Sudeep Karve, 266523

REAL WORLD ASSESSMENT OF PRACTICE EFFICIENCY WITH THE INTRODUCTION OF SUBCUTANEOUS RITUXIMAB

EHA Library, Keith Dawson, 266524

TOLERABILITY OF TREATMENTS FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SYSTEMATIC REVIEW

EHA Library, Maria Nassim, 266525

DOES QUALITY OF LIFE IN MULTIPLE MYELOMA PATIENTS DIFFER BETWEEN NATIONALITIES? A EUROPEAN MULTINATIONAL STUDY

EHA Library, Annemieke van Dongen - Leunis, 266526

COMPARISON OF ALLOPURINOL AND FEBUXOSTAT FOR PREVENTION OF HYPERURICEMIA AND TUMOR LYSIS SYNDROME IN ACUTE LEUKEMIAS

EHA Library, Sumeet Mirgh, 266527

LONG-TERM PROTEASOME INHIBITION (LTPI) IN PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): US MM-6, A REAL-WORLD (RW) STUDY TRANSITIONING FROM BORTEZOMIB (BTZ) TO IXAZOMIB (IXA)

EHA Library, Robert M. Rifkin, 266528

CHRONIC RENAL FAILURE IN CHILDHOOD CANCER: AN INSIGHT FROM KIDS INPATIENT DATABASE

EHA Library, Eman M. Elsabbagh, 266529

A STRATEGY FOR THE MEASUREMENT OF SICKLE CELL DISEASE SYMPTOMS FROM THE PATIENT PERSPECTIVE

EHA Library, Funke Ojo, 266530